Aerobic activity can reduce the risk of metastatic cancer by 72%

by Tel Aviv UniversityCredit: Pixabay/CC0 Public DomainA new study at Tel Aviv University found that aerobic exercise can reduce the risk of metastatic cancer by 72%. According to the researchers

Updated on: February 23,2024

Aerobic activity can reduce the risk of metastatic cancer by 72%

by Tel Aviv UniversityCredit: Pixabay/CC0 Public DomainA new study at Tel Aviv University found that aerobic exercise can reduce the risk of metastatic cancer by 72%. According to the researchers

Updated on:February 23,2024

Study: Innovative pancreatic cancer treatment may rev up immune system

by University of Rochester Medical CenterImmune cells (orange) and blood vessels (green) inside a tumor. Credit: University of Rochester Medical CenterA University of Rochester Wilmot Cancer Inst

Updated on: March 01,2024

Study: Innovative pancreatic cancer treatment may rev up immune system

by University of Rochester Medical CenterImmune cells (orange) and blood vessels (green) inside a tumor. Credit: University of Rochester Medical CenterA University of Rochester Wilmot Cancer Inst

Updated on:March 01,2024

Tumors backfire on chemotherapy

by Ecole Polytechnique Federale de LausanneEndothelial cells (blue/grey) internalizing exosomes (red) released from chemotherapy-treated tumors. Credit: C. Cianciaruso/I. Keklikoglou/EPFLSome pat

Updated on: April 07,2024

Tumors backfire on chemotherapy

by Ecole Polytechnique Federale de LausanneEndothelial cells (blue/grey) internalizing exosomes (red) released from chemotherapy-treated tumors. Credit: C. Cianciaruso/I. Keklikoglou/EPFLSome pat

Updated on:April 07,2024

Old chemo drug, new pancreatic cancer therapy?

Updated on: September 10,2024

Old chemo drug, new pancreatic cancer therapy?

Updated on:September 10,2024

Subtyping of breast cancer cell lines reveals insights into cancer-relevant genes

by Manuela Schüngel, Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbHWaterfall plot depicting recurrent non-synonymous mutations in BC cell lines. Mutations were calle

Updated on: March 30,2024

Subtyping of breast cancer cell lines reveals insights into cancer-relevant genes

by Manuela Schüngel, Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbHWaterfall plot depicting recurrent non-synonymous mutations in BC cell lines. Mutations were calle

Updated on:March 30,2024

Study finds the mechanism used by metastatic cancer cells to infiltrate the liver

by ResearchSEAThe liver sinusoidal endothelial cells (LSECs, beige) surround a blood vessel containing a cancer cell (green). The cancer cell is able to induce the formation of intracellular gaps

Updated on: January 30,2024

Study finds the mechanism used by metastatic cancer cells to infiltrate the liver

by ResearchSEAThe liver sinusoidal endothelial cells (LSECs, beige) surround a blood vessel containing a cancer cell (green). The cancer cell is able to induce the formation of intracellular gaps

Updated on:January 30,2024

Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283

Updated on: February 03,2024

Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283

Updated on:February 03,2024

Research raises hopes for new treatment of fusion-driven cancer

by Aarhus UniversityFusion-gene disruption strategy.ADual intron-targeting CRISPR-Cas9-mediated disruption ofRUNX1-RUNX1T1. sgRNAs targeting intron 4 ofRUNX1(orange)

Updated on: February 03,2024

Research raises hopes for new treatment of fusion-driven cancer

by Aarhus UniversityFusion-gene disruption strategy.ADual intron-targeting CRISPR-Cas9-mediated disruption ofRUNX1-RUNX1T1. sgRNAs targeting intron 4 ofRUNX1(orange)

Updated on:February 03,2024

Beating cancer-related fatigue with personalized interventions

byUniversity of TwenteFlow diagram of selection of eligible studies. Credit:European Journal of Cancer Care(2022). DOI: 10.1111/ecc.13754After diagnosis and treatment of breast cance

Updated on: January 07,2024

Beating cancer-related fatigue with personalized interventions

byUniversity of TwenteFlow diagram of selection of eligible studies. Credit:European Journal of Cancer Care(2022). DOI: 10.1111/ecc.13754After diagnosis and treatment of breast cance

Updated on:January 07,2024

Researchers develop new one-two punch against melanoma in mouse model

by Johns Hopkins University School of MedicineCredit: Kimmel Cancer CenterResearchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University

Updated on: June 04,2024

Researchers develop new one-two punch against melanoma in mouse model

by Johns Hopkins University School of MedicineCredit: Kimmel Cancer CenterResearchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University

Updated on:June 04,2024

Researchers uncover new targets for breast cancers resistant to standard therapies

by Leslie Cantu,Medical University of South CarolinaSOC therapy commonly induces DNA damage, BRCAness and toxic PARP1 trapping, leading to transcriptional blockage and growth inhibition in ER+ b

Updated on: June 22,2024

Researchers uncover new targets for breast cancers resistant to standard therapies

by Leslie Cantu,Medical University of South CarolinaSOC therapy commonly induces DNA damage, BRCAness and toxic PARP1 trapping, leading to transcriptional blockage and growth inhibition in ER+ b

Updated on:June 22,2024

Researchers exploit DNA amplification in cancer to halt chemoresistance

by Stony Brook UniversityGábor Balázsi, in his Biomedical Engineering laboratory with Rafal Krzysztoń, PhD, and Yiming Wan, PhD, both first co-authors on thePNASpaper. Credit: John Gr

Updated on: June 08,2024

Researchers exploit DNA amplification in cancer to halt chemoresistance

by Stony Brook UniversityGábor Balázsi, in his Biomedical Engineering laboratory with Rafal Krzysztoń, PhD, and Yiming Wan, PhD, both first co-authors on thePNASpaper. Credit: John Gr

Updated on:June 08,2024